Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR1334440

GTEX

502aa9e4-d7eb-5b5d-9553-66bb83daf139

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.470
  • PANCREAS_BETA_CELLS+0.389
  • ANGIOGENESIS+0.332
  • INFLAMMATORY_RESPONSE+0.300
  • COAGULATION+0.267
  • ALLOGRAFT_REJECTION+0.265
  • IL6_JAK_STAT3_SIGNALING+0.253
  • APICAL_SURFACE+0.252
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.226
  • SPERMATOGENESIS+0.223

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.618
  • MYC_TARGETS_V1-0.604
  • MYC_TARGETS_V2-0.551
  • DNA_REPAIR-0.535
  • UNFOLDED_PROTEIN_RESPONSE-0.502
  • PROTEIN_SECRETION-0.491
  • ADIPOGENESIS-0.462
  • MTORC1_SIGNALING-0.462
  • FATTY_ACID_METABOLISM-0.446
  • E2F_TARGETS-0.409

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1416410
brain-umap@2
GTEX—0.975
2SRR1475803
brain-umap@2
GTEX—0.974
3SRR1487295
brain-umap@2
GTEX—0.973
4SRR1443979
brain-umap@2
GTEX—0.972
5MDT-AP-1142
medullo-epn-umap@date-based
MedMedulloblastoma0.967
6SRR1387032
brain-umap@2
GTEX—0.966
7SRR1448226
brain-umap@2
GTEX—0.965
8SRR1459423
brain-umap@2
GTEX—0.959
9SRR12202435
bladder-landscape@3
——0.959
10MDT-AP-0225
medullo-epn-umap@date-based
MedMedulloblastoma0.958

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 18 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.470Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.389Cobimetinib— uncovered
ANGIOGENESIS0.332Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.300Idelalisib— uncovered
COAGULATION0.267Binimetinib— uncovered
ALLOGRAFT_REJECTION0.265Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.253Inavolisib— uncovered
APICAL_SURFACE0.252Temsirolimus— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.226Inavolisib— uncovered
SPERMATOGENESIS0.223Inavolisib— uncovered
KRAS_SIGNALING_UP0.221Inavolisib— uncovered
MYOGENESIS0.122Inavolisib— uncovered
APICAL_JUNCTION0.113Inavolisib— uncovered
HEDGEHOG_SIGNALING0.104Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.102Inavolisib— uncovered
COMPLEMENT0.091Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.038Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.005Inavolisib— uncovered